- Home
- CTMX vs PRLD Comparison
CTMX vs PRLD Comparison
Compare CTMX & PRLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CTMX | PRLD |
|---|---|---|
| Founded | 2008 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 596.2M | 69.1M |
| IPO Year | 2015 | 2020 |
Fundamental Metrics
Financial Performance| Metric | CTMX | PRLD |
|---|---|---|
| Price | $4.18 | $2.00 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 3 |
| Target Price | ★ $6.50 | $4.00 |
| AVG Volume (30 Days) | ★ 2.1M | 405.7K |
| Earning Date | 11-06-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 50.22 | N/A |
| EPS | ★ 0.24 | N/A |
| Revenue | ★ $113,631,000.00 | $10,500,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $17.49 | ★ N/A |
| Revenue Growth | N/A | ★ 250.00 |
| 52 Week Low | $0.40 | $0.61 |
| 52 Week High | $4.62 | $4.22 |
Technical Indicators
Market Signals| Indicator | CTMX | PRLD |
|---|---|---|
| Relative Strength Index (RSI) | 57.94 | 60.34 |
| Support Level | $3.78 | $1.60 |
| Resistance Level | $4.25 | $1.72 |
| Average True Range (ATR) | 0.23 | 0.16 |
| MACD | -0.00 | 0.05 |
| Stochastic Oscillator | 79.85 | 89.54 |
Price Performance
Historical ComparisonAbout CTMX CytomX Therapeutics Inc.
CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.
About PRLD Prelude Therapeutics Incorporated
Prelude Therapeutics Incorp is a clinical stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet needs. The company's pipeline includes four candidates currently in clinical development: PRT1419, a potent, selective inhibitor of MCL1; PRT2527, a potent and selective CDK9 inhibitor, PRT3645, a next-generation CDK4/6 inhibitor, and PRT3789 a first-in-class SMARCA2/BRM protein degrader.